Results 231 to 240 of about 118,558 (284)
Exploring new protein biomarkers and therapeutic targets for ankylosing spondylitis through integrated analysis of human plasma proteomics. [PDF]
Medicine (Baltimore)Zeng W, Li Y, Zhang Y, Liu X, Liu S.
europepmc +1 more source
Longitudinal Immune Profiling of T Cell Exhaustion During IL-17A Blockade in a Patient With HLA-B27-negative Spondyloarthritis and Sjögren's Syndrome: A Case Report. [PDF]
In VivoSu YS +6 more
europepmc +1 more source
Case Report: Long-term improvement after acupotomy in advanced ankylosing spondylitis with sacroiliac joint fusion. [PDF]
Front SurgChen Y +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Osteoimmunological insights into the pathogenesis of ankylosing spondylitis
Journal of Cellular Physiology, 2021Ankylosing spondylitis (AS) is inflammatory arthritis predominantly affecting the spine, which is involved in the disorders of both immune and skeletal systems. The exact pathogenesis of AS is not fully understood.
Lifei Liu +4 more
semanticscholar +1 more source
Scottish Medical Journal, 2007
Ankylosing spondylitis is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, which can lead to structural and functional impairments and a decrease in quality of life. New imaging techniques and therapies have substantially changed the management of this disease in the past decade ...
M M, Chee, R D, Sturrock
openaire +4 more sources
Ankylosing spondylitis is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, which can lead to structural and functional impairments and a decrease in quality of life. New imaging techniques and therapies have substantially changed the management of this disease in the past decade ...
M M, Chee, R D, Sturrock
openaire +4 more sources
The Lancet, 2019
BACKGROUND The JAK pathway is a potential therapeutic target in ankylosing spondylitis. This study assessed the efficacy and safety of upadacitinib, a selective JAK1 inhibitor, in patients with ankylosing spondylitis.
D. van der Heijde +12 more
semanticscholar +1 more source
BACKGROUND The JAK pathway is a potential therapeutic target in ankylosing spondylitis. This study assessed the efficacy and safety of upadacitinib, a selective JAK1 inhibitor, in patients with ankylosing spondylitis.
D. van der Heijde +12 more
semanticscholar +1 more source